astellas.comAstellas Pharma Inc. GLOBAL WEBSITE

Sorry, you need to enable JavaScript to visit this website. Skip to main content Search Search About Philosophy Charter of Corporate Conduct President and CEO’s Message Vision & Strategy Corporate Governance Group Code of Conduct Corporate Information Subsidiaries & Locations History Board of Directors Top Management Main Products Policies & Position Statements Ethics & Compliance Medical Care & Pharmaceutical Information Recommended Strategic Plan 2018 Read More Science Focus Area Approach Global Innovation Hub Rx+® Data, Informatics and Analytics Major Pipeline Clinical Trials Investigator Sponsored Research Recommended Focus Area Approach The Focus Area, where we put our efforts, consists of combinations of three components: 1) biology, 2) modality/technology, 3) diseases. Read More Partnering Areas of Interest Why Partner with Astellas Primary Focus and Its Candidate Blindness & Regeneration ASIM Biology/Multi-immune Regulation Mitochondria Biology Genetic Regulation Immuno-Oncology Biology, Modality/Technology of Interest Innate Immunity (Innate Lymphoid Cells) Autophagy Protein Knockdown Cell Therapy Rx+® - New Healthcare Solutions Beyond Medicine Chronic Disease Progression Prevention Motor Function Support/Replacement Digital × Neuroscience Patient w/o Effective Medicines Patient Outcome Maximization via Precise Surgery/Diagnosis Sensory Function Support/Replacement Partnering Teams Get in Touch Recommended Areas of Interest Astellas monitors Focus Areas from biology perspectives, modality/technology, and disease to identify promising areas for investment. Read More Responsibility Our Commitment United Global Compact CSR-Based Management Materiality SDGs ISO26000 30% Club Stakeholder Communications Communication with the World Anti-Doping Agency (WADA) CSR Activities in Five Fields Business Activities ISO certification status of Astellas plants With our Business Partners Basic policy for procurement activities involving suppliers Modern Slavery Act 2015 Society Advancement of Medical Sciences Changing Tomorrow Day Astellas Foundation Environment Definition of terms EHS Management Status of obtaining ISO 14001 Certification Astellas Environment, Health & Safety Guidelines Environment Initiatives Climate Change Mitigation Measures Breakdown of Energy Consumption Sustainable Biodiversity Initiatives Biodiversity and Astellas An Enlarged Version The Biodiversity Burden Index and Revenue Initiatives for Resource Recycling Initiatives for Preventing Pollution Further information on PRTR system Environmental Impact of Products and Countermeasures Environmental Accounting Environment-related Investments and Expenses Reporting coverage, methods, etc. EHS Report Independent Assurance Report EMPLOYEES HR Vision Providing Opportunities for Employees to Succeed Globally Diversity Management Promoting Health Management Occupational Health & Safety Respect for Human Rights Data Ethics & Compliance Access to Health Research Activities on Tuberculosis and Malaria Research Activities on NTDs Access Accelerated Action on Fistula Development of Pediatric Formulation for Schistosomiasis GHIT Fund Awards & Recognition Recommended Access Accelerated Astellas participates in Access Accelerated. Access Accelerated is a first-of-its-kind, multi-stakeholder collaboration focused on improving... Read More News News Stories Recommended Stories The “Story” section contains contents focused on “hero”: people (patients, employees, scientists, etc.), scientific innovation and social... Read More Investors Strategic Plan 2018 Financial Information Financial Highlights Financial Data (Annual Data) Financial Data (Quarterly Data) Sales of Major Products Revenue by Region Annual Report IR Library Business Results Overview of R&D Pipeline IR Meetings Corporate Governance Materials IR Calendar Stock & Rating Information Shareholders Meeting Shareholder Return Current Share Status Chart Issuer Rating Cautionary Statement Analyst Coverage Recommended Financial Information Review our consolidated business results, forecasts and financial data, etc. Read More Common header menu IMPORTANT NOTICE WORLDWIDE Important Notice This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development on this web site. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider. I Agree Thank you for visiting the Astellas Pharma Inc. Website. You will enter external sites beyond here. (This link opens in a new window) Cancel Click here to leave this site. Previous Pause Next Astellas’ Efforts Against the Spread of COVID-19 Read More Partnering with Astellas Astellas leverages our science-first mindset to turn medical advances into VALUE for patients. We are pursuing collaboration with the Best Science partners. Read More Science First and Foremost Astellas combats disease with the formidable combination of ground-breaking biology and modality/technology through our Focus Area approach. Read More ANNUAL REPORT 2019 For the Year Ended March 31, 2019 Read More 1 2 3 4 News Latest Media IR CSR Stories News / General News Jun 16, 2020 Astellas’ Efforts Against the Spread of the Coronavirus Disease (COVID-19) Read More News / Media Jun 08, 2020 Roxadustat Demonstrates Non-Inferiority to Darbepoetin in Phase 3 DOLOMITES Study of Anemia in Non-Dialysis-Dependent Adult Patients with Chronic Kidney Disease Read More News / Media Jun 05, 2020 Astellas, City of Yokohama, and Yokohama City University Developed Science-Based Exercise Programs through Industry-Government-Academia Collaboration Read More News / Media Jun 01, 2020 Final PROSPER Results Show XTANDI ® (enzalutamide) Significantly Extends Overall Survival in Men with Non-Metastatic Castration-Resistant Prostate Cancer Read More News / Media May 29, 2020 XTANDI ® (enzalutamide) Approved by Japan MHLW for the Treatment of Prostate Cancer with Distant Metastasis Read More News / IR May 27, 2020 Posted Notice of Convocation of the 15 th Term Annual Shareholders Read More View more >> News / Media Jun 08, 2020 Roxadustat Demonstrates Non-Inferiority to Darbepoetin in Phase 3 DOLOMITES Study of Anemia in Non-Dialysis-Dependent Adult Patients with Chronic Kidney Disease Read More News / Media Jun 05, 2020 Astellas, City of Yokohama, and Yokohama City University Developed Science-Based Exercise Programs through Industry-Government-Academia Collaboration Read More News / Media Jun 01, 2020 Final PROSPER Results Show XTANDI ® (enzalutamide) Significantly Extends Overall Survival in Men with Non-Metastatic Castration-Resistant Prostate Cancer Read More News / Media May 29, 2020 XTANDI ® (enzalutamide) Approved by Japan MHLW for the Treatment of Prostate Cancer with Distant Metastasis Read More News / Media May 21, 2020 European Medicines Agency Accepts Astellas’ Marketing Authorization Application for Roxadustat Read More News / Media May 20, 2020 Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme Read More View more >> News / IR May 27, 2020 Posted Notice of Convocation of the 15 th Term Annual Shareholders Read More News / IR May 14, 2020 Posted Financial Results for FY2019 Read More News / IR Jan 31, 2020 Posted Financial Results for 3Q/FY2019 Read More News / IR Dec 10, 2019 Updated “R&D Meeting” Section Read More News / IR Dec 03, 2019 Posted Presentation Slides for Conference Call :Acquisition of Audentes Read More News / IR Oct 31, 2019 Posted Financial Results for 2Q/FY2019 Read More View more >> News / Stories Oct 26, 2016 Astellas Uses C 3 Prize to Look Beyo...